BioNTech (NASDAQ:BNTX) Rating Increased to Outperform at Evercore ISI

Evercore ISI upgraded shares of BioNTech (NASDAQ:BNTX) from an in-line rating to an outperform rating in a report released on Tuesday morning, Marketbeat reports. Evercore ISI currently has $125.00 price objective on the stock, up from their prior price objective of $110.00.

Several other equities research analysts have also commented on the stock. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. JPMorgan Chase & Co. cut their price target on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a research note on Monday, November 4th. HC Wainwright restated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Finally, UBS Group lifted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $138.79.

BioNTech Price Performance

Shares of BNTX opened at $113.13 on Tuesday. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The firm’s fifty day simple moving average is $113.60 and its 200-day simple moving average is $97.70. The firm has a market capitalization of $27.12 billion, a price-to-earnings ratio of -53.87 and a beta of 0.26. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period last year, the business earned $0.73 EPS. The company’s revenue was up 38.9% on a year-over-year basis. Equities analysts forecast that BioNTech will post -3.68 EPS for the current fiscal year.

Institutional Trading of BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vestcor Inc purchased a new stake in BioNTech during the third quarter worth about $784,000. Y Intercept Hong Kong Ltd purchased a new stake in BioNTech during the third quarter worth about $718,000. XTX Topco Ltd purchased a new stake in shares of BioNTech in the third quarter valued at about $459,000. State Street Corp grew its position in shares of BioNTech by 2.0% in the third quarter. State Street Corp now owns 155,867 shares of the company’s stock valued at $18,512,000 after purchasing an additional 3,014 shares during the last quarter. Finally, Redmile Group LLC purchased a new position in shares of BioNTech during the 3rd quarter worth approximately $18,345,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.